These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34795952)

  • 1. Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study protocol for a multicenter, randomized, open-label, parallel-group, interventional trial.
    Doi R; Miyazaki T; Tsuchiya T; Matsumoto K; Tomoshige K; Machino R; Mizoguchi S; Matsumoto T; Yamaguchi K; Takatsuna H; Shiosakai K; Nagayasu T
    J Thorac Dis; 2021 Oct; 13(10):6062-6070. PubMed ID: 34795952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of add-on mirogabalin to conventional therapy for the treatment of peripheral neuropathic pain after thoracic surgery: the multicenter, randomized, open-label ADMIT-NeP study.
    Miyazaki T; Matsumoto K; Sato T; Sano I; Furukawa K; Shimoyama K; Kamohara R; Suzuki M; Kondou M; Ikeda N; Tabata S; Shiosakai K; Nagayasu T;
    BMC Cancer; 2024 Jan; 24(1):80. PubMed ID: 38225552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study.
    Nikaido T; Takatsuna H; Tabata S; Shiosakai K; Nakatani T; Konno SI
    Pain Ther; 2022 Dec; 11(4):1195-1214. PubMed ID: 35857196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia.
    Ushida T; Katayama Y; Hiasa Y; Nishihara M; Tajima F; Katoh S; Tanaka H; Maeda T; Furusawa K; Kakehi Y; Kikumori K; Kuroha M
    Pain Ther; 2023 Aug; 12(4):963-978. PubMed ID: 37115464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching From Pregabalin to Mirogabalin in Patients with Peripheral Neuropathic Pain: A Multi-Center, Prospective, Single-Arm, Open-Label Study (MIROP Study).
    Kimura Y; Yamaguchi S; Suzuki T; Kato J; Chiba S; Hirakawa N; Yamaguchi K; Tanabe Y; Takatsuna H; Kenyoshi Y; Shiosakai K; Sakai M; Iseki M
    Pain Ther; 2021 Jun; 10(1):711-727. PubMed ID: 33856660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies.
    Kato J; Baba M; Kuroha M; Kakehi Y; Murayama E; Wasaki Y; Ohwada S
    Clin Ther; 2021 May; 43(5):822-835.e16. PubMed ID: 34059327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia.
    Ushida T; Katayama Y; Hiasa Y; Nishihara M; Tajima F; Katoh S; Tanaka H; Maeda T; Furusawa K; Richardson M; Kakehi Y; Kikumori K; Kuroha M
    Neurology; 2023 Mar; 100(11):e1193-e1206. PubMed ID: 36517235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mirogabalin in Japanese Patients with Renal Impairment and Pain Associated with Diabetic Peripheral Neuropathy or Post-Herpetic Neuralgia: A Phase III, Open-Label, 14-Week Study.
    Baba M; Takatsuna H; Matsui N; Ohwada S
    J Pain Res; 2020; 13():1811-1821. PubMed ID: 32765056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled 14-Week Study of Mirogabalin in Chinese Patients with Diabetic Peripheral Neuropathic Pain.
    Guo X; Yu Y; Zhang Y; Sun L; Li Y; Song B; Hang L; Baba M; Wasaki Y; Kikumori K; Murayama E
    Pain Ther; 2024 Jun; ():. PubMed ID: 38896199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain.
    Baba M; Matsui N; Kuroha M; Wasaki Y; Ohwada S
    J Diabetes Investig; 2020 May; 11(3):693-698. PubMed ID: 31722446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study.
    Baba M; Kuroha M; Ohwada S; Murayama E; Matsui N
    Pain Ther; 2020 Jun; 9(1):261-278. PubMed ID: 32052264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study.
    Arnold LM; Whitaker S; Hsu C; Jacobs D; Merante D
    Curr Med Res Opin; 2019 Oct; 35(10):1825-1835. PubMed ID: 31284771
    [No Abstract]   [Full Text] [Related]  

  • 14. Usefulness of Mirogabalin in Central Neuropathic Pain After Stroke: Post Hoc Analysis of a Phase 3 Study by Stroke Type and Location.
    Hosomi K; Katayama Y; Sakoda H; Kikumori K; Kuroha M; Ushida T
    Pain Ther; 2024 Jul; ():. PubMed ID: 38963656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirogabalin as a Therapeutic Option for Neuropathic Pain Emerging Post-endodontic Treatment: A Two-Case Report.
    Shimizu K; Yasukawa T; Ohara K; Noma N; Hayashi M; Takeichi O
    J Endod; 2024 Jun; ():. PubMed ID: 38901645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study.
    Tetsunaga T; Tetsunaga T; Nishida K; Misawa H; Takigawa T; Yamane K; Tsuji H; Takei Y; Ozaki T
    J Orthop Surg Res; 2020 May; 15(1):191. PubMed ID: 32456647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin.
    Yamanaka T; Takeshita K; Mochizuki T; Inoue H; Akiyama T
    Spine Surg Relat Res; 2023 Mar; 7(2):136-141. PubMed ID: 37041868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mirogabalin-A Novel Selective Ligand for the α2δ Calcium Channel Subunit.
    Zajączkowska R; Mika J; Leppert W; Kocot-Kępska M; Malec-Milewska M; Wordliczek J
    Pharmaceuticals (Basel); 2021 Jan; 14(2):. PubMed ID: 33572689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somnolence and Dizziness During Mirogabalin Treatment in Patients With Neuropathic Pain Related to Lumbar Disease Who Switched From Pregabalin: A Retrospective Study.
    Akazawa T; Inoue G; Tanaka M; Umehara T; Nagai T; Oshita Y; Imura T; Miyagi M; Saito W; Sako K; Nomura S; Hiyama A; Katoh H; Sakai D; Sato M; Yoshida A; Iinuma M; Niki H; Takaso M; Watanabe M
    Global Spine J; 2023 Jun; 13(5):1319-1324. PubMed ID: 34325544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.